Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.

Schlumberger C, Pietraszek M, Gravius A, Klein KU, Greco S, Morè L, Danysz W.

Eur J Pharmacol. 2009 Nov 25;623(1-3):73-83. doi: 10.1016/j.ejphar.2009.09.006. Epub 2009 Sep 16.

PMID:
19765575
2.

In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).

Fell MJ, Perry KW, Falcone JF, Johnson BG, Barth VN, Rash KS, Lucaites VL, Threlkeld PG, Monn JA, McKinzie DL, Marek GJ, Svensson KA, Nelson DL.

J Pharmacol Exp Ther. 2009 Dec;331(3):1126-36. doi: 10.1124/jpet.109.160598. Epub 2009 Sep 15.

3.

Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants.

Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, Vardigan JD, Hutson PH.

Psychopharmacology (Berl). 2009 Nov;206(4):641-51. doi: 10.1007/s00213-009-1644-y. Epub 2009 Aug 26.

PMID:
19707745
4.

Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors.

Seeman P, Guan HC.

Synapse. 2009 Aug;63(8):705-9. doi: 10.1002/syn.20673.

PMID:
19391149
5.

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.

Schlumberger C, Schäfer D, Barberi C, Morè L, Nagel J, Pietraszek M, Schmidt WJ, Danysz W.

Behav Pharmacol. 2009 Feb;20(1):56-66. doi: 10.1097/FBP.0b013e3283242f57.

PMID:
19179851
6.

PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.

Guillot TS, Richardson JR, Wang MZ, Li YJ, Taylor TN, Ciliax BJ, Zachrisson O, Mercer A, Miller GW.

Neuropeptides. 2008 Aug;42(4):423-34. doi: 10.1016/j.npep.2008.04.003. Epub 2008 Jun 3.

8.

Differential tonic influence of lateral habenula on prefrontal cortex and nucleus accumbens dopamine release.

Lecourtier L, Defrancesco A, Moghaddam B.

Eur J Neurosci. 2008 Apr;27(7):1755-62. doi: 10.1111/j.1460-9568.2008.06130.x.

9.

Identification of a serotonin/glutamate receptor complex implicated in psychosis.

González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC.

Nature. 2008 Mar 6;452(7183):93-7. doi: 10.1038/nature06612. Epub 2008 Feb 24.

10.

Glutamate agonists for schizophrenia stimulate dopamine D2High receptors.

Seeman P.

Schizophr Res. 2008 Feb;99(1-3):373-4. No abstract available.

PMID:
18077139
11.

The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.

Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN.

Psychopharmacology (Berl). 2008 Feb;196(3):431-40. Epub 2007 Dec 5.

PMID:
18057917
12.

Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268.

Seeman P, Caruso C, Lasaga M.

Synapse. 2008 Feb;62(2):154-8.

PMID:
18000815
13.

Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism.

Lanteri C, Salomon L, Torrens Y, Glowinski J, Tassin JP.

Neuropsychopharmacology. 2008 Jun;33(7):1724-34. Epub 2007 Sep 5.

14.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.

Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD.

Nat Med. 2007 Sep;13(9):1102-7. Epub 2007 Sep 2. Erratum in: Nat Med. 2007 Oct;13(10):1264.

PMID:
17767166
15.

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD.

Psychopharmacology (Berl). 2007 Jul;193(1):121-36. Epub 2007 Mar 24.

PMID:
17384937
16.

A glutamate-dopamine interaction in the persistent enhanced response to amphetamine in nucleus accumbens core but not shell following a single restraint stress.

Pacchioni AM, Cador M, Bregonzio C, Cancela LM.

Neuropsychopharmacology. 2007 Mar;32(3):682-92. Epub 2006 Apr 19.

17.

A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell.

Karasawa J, Yoshimizu T, Chaki S.

Neurosci Lett. 2006 Jan 30;393(2-3):127-30. Epub 2005 Oct 17.

PMID:
16233956
18.

Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography.

van Berckel BN, Kegeles LS, Waterhouse R, Guo N, Hwang DR, Huang Y, Narendran R, Van Heertum R, Laruelle M.

Neuropsychopharmacology. 2006 May;31(5):967-77.

19.

Mechanisms of neurotransmitter release by amphetamines: a review.

Sulzer D, Sonders MS, Poulsen NW, Galli A.

Prog Neurobiol. 2005 Apr;75(6):406-33. Review.

PMID:
15955613

Supplemental Content

Support Center